Research work · 2004
Inadvertent epidural administration of metaraminol
R. Savage, Charles Beattie
Anaesthesia
Abstract
We report the clinical course of a patient following the inadvertent epidural administration of metaraminol, the immediate concerns, treatment and the factors contributing to this drug error. A 72 year-old man was scheduled for a radical nephrectomy. He was a smoker (15 cigarettes per day), reported good exercise tolerance and was on no medication. On admission his BP was 160/90 mmHg and his ECG demonstrated left ventricular hypertrophy. Pre-operative assessment was otherwise unremarkable. Prior to induction of anaesthesia an awake-low thoracic epidural was performed. General anaesthesia was induced with fentanyl, propofol and atracurium and maintained with oxygen in air and isoflurane. Eighteen ml of bupivacaine 0.25% and fentanyl 100 µg was placed in an appropriately labelled 20 ml syringe using the recently introduced international standardised system. Two 5 ml epidural boluses of this mixture were given during the first hour of the procedure. Hypotension was treated with a combination of fluids, ephedrine and subsequently metaraminol. Towards the end of the procedure, and prior to commencing an epidural infusion, the remainder of the bupivacaine/fentanyl mixture was administered. At this point the blood pressure began to rise becoming more marked with emergence from anaesthesia. It was then noted that metaraminol 7 mg in 14 ml (which was also in a 20 ml syringe and correctly labelled) had been administered instead of the bupivacaine/fentanyl. On transfer to recovery the patient began to develop significant hypertension peaking at 232/113 mmHg 20–30 min following the drug error. This was treated with labetolol 10 mg and a topical nitrate patch (10 mg). The epidural infusion of bupivacaine 0.1% and fentanyl 2 µg.ml-1 was commenced as planned. The nitrate patch was removed after 3 h when the blood pressure had fallen to 130/60 mmHg. The patient was asymptomatic throughout his postoperative period with a good sensory block. He was fully informed of the drug error and full neurological examination 5 days later was normal aside from a small area of reduced sensation below his wound, probably secondary to the surgery. The manufacturers know of no other similar incidents and a Medline search revealed no other case reports. Our immediate concern of epidural metaraminol was the risk of spinal cord ischaemia due to its vasoconstricting effects. Providing there was no systemic hypotension it was felt that continuing the epidural bupivicaine infusion would do no harm. The only effects of the error were hypertension due to absorption of epidural metaraminol into the systemic circulation. Epidural epinephrine at a concentration of 2 µg.ml-1 has been shown to be safe and to improve the level of analgesia produced by low dose bupivicaine/fentanyl [1]. Kozody et al. studied the effects of lumbar subarachnoid injection of saline, epinephrine and phenylephrine in dogs. They showed that after injection of epinephrine or phenylephrine there was a significant reduction in dural blood flow, however, neither had an effect on spinal cord blood flow [2]. There is conflicting evidence from other studies that have shown that local anaesthetics containing epinephrine can decrease spinal cord blood flow by up to 50%, and that the reduction is greater in the presence of hypotension [3]. There are a number of reports of spinal artery ischaemia or infarction following epidural anaesthesia associated with intra-operative hypotension [4-6]. This could potentially be compounded by the presence of a vasoconsrictor in the solution [7, 8]. Several authors have reviewed the inadvertent injection of drugs via the epidural route [9, 10]. There were no serious sequelae with vecuronium, benzodiazepines, opiods, ephedrine and antibiotics. Other complications included pain with injection of thiopental to transient neurological sequelae with magnesium sulphate and ether. The most serious of complications were noted with potassium chloride causing a range of problems from pain to permanent paraplegia and death 6 months later and with paraldehyde causing immediate pain progressing to quadriplegia. Recent changes from the Medilabel to the ‘international standard’ of colour coding labels for drug syringes has prompted a number of comments about the possibility of drug errors. There is little doubt that although this may have contributed in this case the authors feel that the other factors responsible were human error in reading labels, ‘syringe’ swap (both were 20 ml volume), communication between anaesthetists and compatible intravenous and epidural injection ports.